In December 2024, Akebia announced that U.S. Renal Care enrolled the first patients in VOICE, a collaborative clinical trial of Vafseo designed to assess mortality and hospitalization in patients ...

Purpose: The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. Methods: The study was an observational, retrospective review of the hospitalwide use of ...

Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients.

Darbepoetin was well tolerated and conveniently coordinated with cyclic chemotherapy. Ten patients maintained a hemoglobin concentration of ≥11 g/dL for at least two treatment periods.

and work in a different way to ESAs like epoetin alfa and darbepoetin alfa, which stimulate the production of more blood cells in in the bone marrow. In addition to the added convenience of oral ...